Campos Polo R, et al. - The intent of the experts was to gauge the efficacy and safety profile of intravitreal aflibercept in clinically significant diabetic macular edema (DME) during routine clinical practice. Findings illustrated the effectiveness of aflibercept as a first-line therapy for DME patients. It was found to be well tolerated. Successful results were yielded with regard to the improvement of visual acuity and reduction in central macular thickness. These provided evidence for the positioning of aflibercept as the first-line indication of newly diagnosed clinically significant DME.